Document is current
Any future updates will be listed below
-
Authors
Kim, Yestle https://orcid.org/0009-0007-0263-9384
Medicis, Joe
Davis, Matthew
Nunag, Dominic
Gish, Robert
-
Funding
Funding for this research was provided by:
Madrigal Pharmaceuticals
- License Information
-
More Information
Article History
Received: 25 July 2024
Accepted: 21 August 2024
First Online: 24 September 2024
Declarations
:
: Yestle Kim and Joe Medicis are employees of Madrigal Pharmaceuticals and may own stocks/and or options from Madrigal Pharmaceuticals. Matthew Davis and Dominic Nunag are employees of Medicus Economics, LLC. Medicus Economics, LLC received consulting fees for research from Madrigal Pharmaceuticals. Robert Gish has performed as Consultant and/or Advisor to (in the last two years): Abacus, Abbott, AbbVie, Albireo, Aligos, Altimunne, Arrowhead, AstraZeneca, Audentes Therapeutics, Corcept, Dynavax, Effectus, Eiger, Eisai, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, GlaxoSmithKline, Helios, HepaTX, HepQuant, Intercept, Janssen, JBS Science, Kinnate Bio, Madrigal, Merck, Precision BioSciences, Pfizer, Seres Therapeutics, Topography Health, Tune Therapeutics, Venatorx, Virion.
: An Institutional Review Board exemption was not required for this study as the data were de-identified and compliant with Health Insurance Portability and Accountability Act regulations. This study was conducted according to best practices recommended by the Reporting of Studies Conducted Using Observational Routinely Collected Data for Pharmacoepidemiology (RECORD-PE) guidelines []. This study was performed in accordance with the ethical guidelines of the 1964 Declaration of Helsinki and its subsequent updates. Database permission was provided by CMS.
